Kai Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kai Zhao has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Xueming Xu
Department of Hematology The Third Xiangya Hospital Central South University Changsha Hunan 410000 P. R. China
10 shared publicationsNingjie Zhang
Department of Blood Transfusion, Second Xiangya Hospital, Central South University, Changsha, PR China
9 shared publicationsYening Zhang
Department of Hematology and Critical Care Medicine, Third Xiangya Hospital, Central South University, Changsha, PR China
9 shared publicationsDan Wang
Department of Dermatology The Third Xiangya Hospital Central South University Changsha Hunan 410000 P. R. China
7 shared publicationsRuiheng Luo
Department of Hematology The Third Xiangya Hospital Central South University Changsha Hunan 410000 P. R. China
6 shared publications- Ben Lu
Department of Critical Care Medicine and Hematology, The Third Xiangya Hospital, Central South University; Department of Hematology and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China
5 shared publications
Latest Publications
- Open Access
- 15 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (44) , e04816
GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation
NLRP3 inflammasome is a multiple protein complex sensing exogenous or endogenous stimuli, and aberrant activation of the NLRP3 inflammasome is implicated in various inflammatory disorders. While numerous small‐molecule compounds targeting NLRP3 inflammasome activity have been developed, most have encountered limited success in clinical translation. Through screening of a kinase compound library, GSK461364 is identified as a potent and selective NLRP3 inflammasome inhibitor. Notably, GSK461364 confers significant protective effects in murine models of LPS‐induced endotoxemia and DSS‐induced colitis. Mechanistic study reveals that GSK461364 exerts its inhibitory effects via targeting Polo‐like Kinase 1(PLK1). Specifically, that PLK1‐mediated phosphorylation of NEK7, likely occurring at evolutionarily conserved serine residues (Ser221 and Ser260), is shown to enhance NEK7‐NLRP3 binding, a critical step for NLRP3 inflammasome assembly. These findings not only establish GSK461364 as a novel therapeutic candidate for NLRP3‐driven inflammatory diseases but also provide new insights into the regulatory mechanisms governing inflammasome activation through post‐translational modification.
- 15 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (44) , e04816
Open AccessGSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation
NLRP3 inflammasome is a multiple protein complex sensing exogenous or endogenous stimuli, and aberrant activation of the NLRP3 inflammasome is implicated in various inflammatory disorders. While numerous small‐molecule compounds targeting NLRP3 inflammasome activity have been developed, most have encountered limited success in clinical translation. Through screening of a kinase compound library, GSK461364 is identified as a potent and selective NLRP3 inflammasome inhibitor. Notably, GSK461364 confers significant protective effects in murine models of LPS‐induced endotoxemia and DSS‐induced colitis. Mechanistic study reveals that GSK461364 exerts its inhibitory effects via targeting Polo‐like Kinase 1(PLK1). Specifically, that PLK1‐mediated phosphorylation of NEK7, likely occurring at evolutionarily conserved serine residues (Ser221 and Ser260), is shown to enhance NEK7‐NLRP3 binding, a critical step for NLRP3 inflammasome assembly. These findings not only establish GSK461364 as a novel therapeutic candidate for NLRP3‐driven inflammatory diseases but also provide new insights into the regulatory mechanisms governing inflammasome activation through post‐translational modification.
- Open Access
- 27 September 2024
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 56 (9) , 2097
Author Correction: STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation
- 27 September 2024
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 56 (9) , 2097
Open AccessAuthor Correction: STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation
- Open Access
- 2 September 2024
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 56 (9) , 1980-1990
STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation
Recognition of the translocation of NLRP3 to various organelles has provided new insights for understanding how the NLRP3 inflammasome is activated by different stimuli. Mitochondria have already been demonstrated to be the site of NLRP3 inflammasome activation, and the latest research suggests that NLRP3 is first recruited to mitochondria, then disassociated, and subsequently recruited to the Golgi network. Although some mitochondrial factors have been found to contribute to the recruitment of NLRP3 to mitochondria, the detailed process of NLRP3 mitochondrial translocation remains unclear. Here, we identify a previously unknown role for Signal transducer and activator of transcription-3 (STAT3) in facilitating the translocation of NLRP3 to mitochondria. STAT3 interacts with NLRP3 and undergoes phosphorylation at Ser727 in response to several NLRP3 agonists, enabling the translocation of STAT3 and thus the bound NLRP3 to mitochondria. Disruption of the interaction between STAT3 and NLRP3 impairs the mitochondrial localization of NLRP3, specifically suppressing NLRP3 inflammasome activation both in vitro and in vivo. In summary, we demonstrate that STAT3 acts as a transporter for mitochondrial translocation of NLRP3 and provide new insight into the spatial regulation of NLRP3.
- 2 September 2024
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 56 (9) , 1980-1990
Open AccessSTAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation
Recognition of the translocation of NLRP3 to various organelles has provided new insights for understanding how the NLRP3 inflammasome is activated by different stimuli. Mitochondria have already been demonstrated to be the site of NLRP3 inflammasome activation, and the latest research suggests that NLRP3 is first recruited to mitochondria, then disassociated, and subsequently recruited to the Golgi network. Although some mitochondrial factors have been found to contribute to the recruitment of NLRP3 to mitochondria, the detailed process of NLRP3 mitochondrial translocation remains unclear. Here, we identify a previously unknown role for Signal transducer and activator of transcription-3 (STAT3) in facilitating the translocation of NLRP3 to mitochondria. STAT3 interacts with NLRP3 and undergoes phosphorylation at Ser727 in response to several NLRP3 agonists, enabling the translocation of STAT3 and thus the bound NLRP3 to mitochondria. Disruption of the interaction between STAT3 and NLRP3 impairs the mitochondrial localization of NLRP3, specifically suppressing NLRP3 inflammasome activation both in vitro and in vivo. In summary, we demonstrate that STAT3 acts as a transporter for mitochondrial translocation of NLRP3 and provide new insight into the spatial regulation of NLRP3.
- Open Access
- 15 March 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (6) , 2698-2715
Repurposing disulfiram with CuET nanocrystals: Enhancing anti-pyroptotic effect through NLRP3 inflammasome inhibition for treating inflammatory bowel diseases
- 15 March 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (6) , 2698-2715
Open AccessRepurposing disulfiram with CuET nanocrystals: Enhancing anti-pyroptotic effect through NLRP3 inflammasome inhibition for treating inflammatory bowel diseases
- Open Access
- 18 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Acetylation is required for full activation of the NLRP3 inflammasome
Full activation of the NLRP3 inflammasome needs two sequential signals: a priming signal, followed by a second, assembly signal. Several studies have shown that the two signals trigger post-translational modification (PTM) of NLRP3, affecting activity of the inflammasome, however, the PTMs induced by the second signal are less well characterized. Here, we show that the assembly signal involves acetylation of NLRP3 at lysine 24, which is important for the oligomerization and the actual assembly of NLRP3 without affecting its recruitment to dispersed trans-Golgi network (dTGN). Accordingly, NLRP3 inflammasome activation is impaired in NLRP3-K24R knock-in mice. We identify KAT5 as an acetyltransferase able to acetylate NLRP3. KAT5 deficiency in myeloid cells and pharmacological inhibition of KAT5 enzymatic activity reduce activation of the NLRP3 inflammasome, both in vitro and in vivo. Thus, our study reveals a key mechanism for the oligomerization and full activation of NLRP3 and lays down the proof of principle for therapeutic targeting of the KAT5-NLRP3 axis.
- 18 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Open AccessAcetylation is required for full activation of the NLRP3 inflammasome
Full activation of the NLRP3 inflammasome needs two sequential signals: a priming signal, followed by a second, assembly signal. Several studies have shown that the two signals trigger post-translational modification (PTM) of NLRP3, affecting activity of the inflammasome, however, the PTMs induced by the second signal are less well characterized. Here, we show that the assembly signal involves acetylation of NLRP3 at lysine 24, which is important for the oligomerization and the actual assembly of NLRP3 without affecting its recruitment to dispersed trans-Golgi network (dTGN). Accordingly, NLRP3 inflammasome activation is impaired in NLRP3-K24R knock-in mice. We identify KAT5 as an acetyltransferase able to acetylate NLRP3. KAT5 deficiency in myeloid cells and pharmacological inhibition of KAT5 enzymatic activity reduce activation of the NLRP3 inflammasome, both in vitro and in vivo. Thus, our study reveals a key mechanism for the oligomerization and full activation of NLRP3 and lays down the proof of principle for therapeutic targeting of the KAT5-NLRP3 axis.
- 21 March 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 118, 110024
Leukadherin-1 inhibits NLRP3 inflammasome by blocking inflammasome assembly
- 21 March 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 118, 110024
Leukadherin-1 inhibits NLRP3 inflammasome by blocking inflammasome assembly
- 6 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 376 (6593) , 609-615
Z-DNA binding protein 1 promotes heatstroke-induced cell death
Heatstroke is a heat stress–induced, life-threatening condition associated with circulatory failure and multiple organ dysfunctions. If global warming continues, heatstroke might become a more prominent cause of mortality worldwide, but its pathogenic mechanism is not well understood. We found that Z-DNA binding protein 1 (ZBP1), a Z–nucleic acid receptor, mediated heatstroke by triggering receptor-interacting protein kinase 3 (RIPK3)–dependent cell death. Heat stress increased the expression of ZBP1 through heat shock transcription factor 1 (HSF1) and activated ZBP1 through a mechanism independent of the nucleic acid sensing action. Deletion of ZBP1, RIPK3, or both mixed lineage kinase domain-like (MLKL) and caspase-8 decreased heat stress–induced circulatory failure, organ injury, and lethality. Thus, ZBP1 appears to have a second function that orchestrates host responses to heat stress.
- 6 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 376 (6593) , 609-615
Z-DNA binding protein 1 promotes heatstroke-induced cell death
Heatstroke is a heat stress–induced, life-threatening condition associated with circulatory failure and multiple organ dysfunctions. If global warming continues, heatstroke might become a more prominent cause of mortality worldwide, but its pathogenic mechanism is not well understood. We found that Z-DNA binding protein 1 (ZBP1), a Z–nucleic acid receptor, mediated heatstroke by triggering receptor-interacting protein kinase 3 (RIPK3)–dependent cell death. Heat stress increased the expression of ZBP1 through heat shock transcription factor 1 (HSF1) and activated ZBP1 through a mechanism independent of the nucleic acid sensing action. Deletion of ZBP1, RIPK3, or both mixed lineage kinase domain-like (MLKL) and caspase-8 decreased heat stress–induced circulatory failure, organ injury, and lethality. Thus, ZBP1 appears to have a second function that orchestrates host responses to heat stress.
- 8 April 2022
- Published by Elsevier in Thrombosis Research
- Vol. 214, 8-15
NLRP3 inflammasome contributes to endotoxin-induced coagulation
- 8 April 2022
- Published by Elsevier in Thrombosis Research
- Vol. 214, 8-15
NLRP3 inflammasome contributes to endotoxin-induced coagulation
- Open Access
- 12 July 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 707610
C646 Protects Against DSS-Induced Colitis Model by Targeting NLRP3 Inflammasome
Numerous pieces of evidence have identified that the NLRP3 inflammasome plays a pivotal role in the development and pathogenesis of colitis. Targeting the NLRP3 inflammasome represents a potential therapeutic treatment. Our previous studies have suggested that acetylation of NLRP3 is indispensable to NLRP3 inflammasome activation, and some acetyltransferase inhibitors could suppress the NLRP3 inflammasome activation. Here, we identified that C646, an inhibitor of histone acetyltransferase p300, exerts anti-inflammatory effects in DSS-induced colitis mice by targeting the NLRP3 inflammasome. Mechanistically, C646 not only inhibits NF-κB activation, leading to the decreased expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and NLRP3, but also suppresses the NLRP3 inflammasome assembly by disrupting the interaction between NLRP3 and ASC. In addition, C646 attenuated the LPS-induced acute systemic inflammation model. Thus, our results demonstrate the ability of C646 to suppress the NLRP3 inflammasome activity and its potential application in the treatment of inflammatory bowel disease.
- 12 July 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 707610
Open AccessC646 Protects Against DSS-Induced Colitis Model by Targeting NLRP3 Inflammasome
Numerous pieces of evidence have identified that the NLRP3 inflammasome plays a pivotal role in the development and pathogenesis of colitis. Targeting the NLRP3 inflammasome represents a potential therapeutic treatment. Our previous studies have suggested that acetylation of NLRP3 is indispensable to NLRP3 inflammasome activation, and some acetyltransferase inhibitors could suppress the NLRP3 inflammasome activation. Here, we identified that C646, an inhibitor of histone acetyltransferase p300, exerts anti-inflammatory effects in DSS-induced colitis mice by targeting the NLRP3 inflammasome. Mechanistically, C646 not only inhibits NF-κB activation, leading to the decreased expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and NLRP3, but also suppresses the NLRP3 inflammasome assembly by disrupting the interaction between NLRP3 and ASC. In addition, C646 attenuated the LPS-induced acute systemic inflammation model. Thus, our results demonstrate the ability of C646 to suppress the NLRP3 inflammasome activity and its potential application in the treatment of inflammatory bowel disease.
- Open Access
- 11 May 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-14
YAP promotes the activation of NLRP3 inflammasome via blocking K27-linked polyubiquitination of NLRP3
The transcription coactivator YAP plays a vital role in Hippo pathway for organ-size control and tissue homeostasis. Recent studies have demonstrated YAP is closely related to immune disorders and inflammatory diseases, but the underlying mechanisms remain less defined. Here, we find that YAP promotes the activation of NLRP3 inflammasome, an intracellular multi-protein complex that orchestrates host immune responses to infections or sterile injuries. YAP deficiency in myeloid cells significantly attenuates LPS-induced systemic inflammation and monosodium urate (MSU) crystals-induced peritonitis. Mechanistically, YAP physically interacts with NLRP3 and maintains the stability of NLRP3 through blocking the association between NLRP3 and the E3 ligase β-TrCP1, the latter increases the proteasomal degradation of NLRP3 via K27-linked ubiquitination at lys380. Together, these findings establish a role of YAP in the activation of NLRP3 inflammasome, and provide potential therapeutic target to treat the NLRP3 inflammasome-related diseases.
- 11 May 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-14
Open AccessYAP promotes the activation of NLRP3 inflammasome via blocking K27-linked polyubiquitination of NLRP3
The transcription coactivator YAP plays a vital role in Hippo pathway for organ-size control and tissue homeostasis. Recent studies have demonstrated YAP is closely related to immune disorders and inflammatory diseases, but the underlying mechanisms remain less defined. Here, we find that YAP promotes the activation of NLRP3 inflammasome, an intracellular multi-protein complex that orchestrates host immune responses to infections or sterile injuries. YAP deficiency in myeloid cells significantly attenuates LPS-induced systemic inflammation and monosodium urate (MSU) crystals-induced peritonitis. Mechanistically, YAP physically interacts with NLRP3 and maintains the stability of NLRP3 through blocking the association between NLRP3 and the E3 ligase β-TrCP1, the latter increases the proteasomal degradation of NLRP3 via K27-linked ubiquitination at lys380. Together, these findings establish a role of YAP in the activation of NLRP3 inflammasome, and provide potential therapeutic target to treat the NLRP3 inflammasome-related diseases.